JP2009529576A - 持続感染または潜伏感染を引き起こすウイルスに対するワクチン - Google Patents

持続感染または潜伏感染を引き起こすウイルスに対するワクチン Download PDF

Info

Publication number
JP2009529576A
JP2009529576A JP2009500402A JP2009500402A JP2009529576A JP 2009529576 A JP2009529576 A JP 2009529576A JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009500402 A JP2009500402 A JP 2009500402A JP 2009529576 A JP2009529576 A JP 2009529576A
Authority
JP
Japan
Prior art keywords
virus
dna
mcmv
mice
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529576A5 (https=
Inventor
デボラ エイチ スペクター
クリストファー エス モレロ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of JP2009529576A publication Critical patent/JP2009529576A/ja
Publication of JP2009529576A5 publication Critical patent/JP2009529576A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009500402A 2006-03-10 2007-03-09 持続感染または潜伏感染を引き起こすウイルスに対するワクチン Pending JP2009529576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78112306P 2006-03-10 2006-03-10
PCT/US2007/006113 WO2007106404A2 (en) 2006-03-10 2007-03-09 Vaccine for viruses that cause persistent or latent infections

Publications (2)

Publication Number Publication Date
JP2009529576A true JP2009529576A (ja) 2009-08-20
JP2009529576A5 JP2009529576A5 (https=) 2010-04-30

Family

ID=38510006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500402A Pending JP2009529576A (ja) 2006-03-10 2007-03-09 持続感染または潜伏感染を引き起こすウイルスに対するワクチン

Country Status (5)

Country Link
US (1) US8501194B2 (https=)
EP (1) EP2001516A4 (https=)
JP (1) JP2009529576A (https=)
CA (1) CA2645507A1 (https=)
WO (1) WO2007106404A2 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009037359A1 (en) * 2007-09-21 2009-03-26 Sanofi Pasteur Vaccine composition for the prevention of cmv infections
EP3756684A1 (en) 2009-05-22 2020-12-30 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US8979890B2 (en) 2010-10-01 2015-03-17 Ethicon Endo-Surgery, Inc. Surgical instrument with jaw member
JP6055776B2 (ja) 2010-11-24 2016-12-27 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対するワクチン：免疫応答を誘発する組成物及び方法
EA033467B1 (ru) * 2011-01-31 2019-10-31 Univ Pennsylvania Молекула нуклеиновой кислоты для индукции иммунного ответа против герпесвируса и ее применение
EP2726097A4 (en) * 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
US20140348863A1 (en) * 2011-10-12 2014-11-27 Alessia Bianchi Cmv antigens and uses thereof
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP3246400B1 (en) * 2012-01-09 2019-10-23 Sanofi Pasteur Biologics, LLC Purification of herpes virus
EP2852662B1 (en) 2012-05-21 2020-09-16 Sanofi Pasteur Limited Herpesvirus compositions and related methods
WO2014005643A1 (en) * 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CA2890061A1 (en) * 2012-12-04 2014-06-12 Merck Sharp & Dohme Corp. Conditional replicating viral vectors
MX384992B (es) 2014-06-13 2025-03-14 Glaxosmithkline Biologicals Sa Combinaciones inmunógenas.
US10314383B2 (en) 2015-03-30 2019-06-11 Gary McClellan Thompson Wearable sports equipment carrier with personal flotation device
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
CN111032681B (zh) * 2017-08-30 2024-05-17 Km生物医薬股份公司 修饰型HSV gB蛋白及包含其的HSV疫苗
MA53158A (fr) * 2018-07-20 2021-05-26 Aicuris Gmbh & Co Kg Procédés de criblage et d'identification d'agents inhibant ou modulant le complexe de sortie nucléaire du virus de l'herpès
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽
CA3230564A1 (en) * 2021-09-13 2023-03-16 Jean-Pol DETIFFE Method to generate personalized neoantigens of a tumor of a patient
EP4147712A1 (en) * 2021-09-13 2023-03-15 OncoDNA Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient
US20250319132A1 (en) * 2024-04-16 2025-10-16 Mirror Biologics, Inc. Methods and compositions for improving the immune response against viral pathogens

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5009001944; ＥＮＤＲＥＳＺ: ＶＡＣＣＩＮＥ Ｖ１７, 1999, Ｐ５０-５８ *
JPN7012003634; ＭＯＲＥＬＬＯ，　Ｃ．　Ｓ．　ｅｔ　ａｌ: 'Ｓｙｓｔｅｍｉｃ　Ｐｒｉｍｉｎｇ-Ｂｏｏｓｔｉｎｇ　Ｉｍｍｕｎｉｚａｔｉｏｎ　ｗｉｔｈ　ａ　Ｔｒｉｖａｌｅｎｔ　Ｐｌａｓｍｉｄ　ＤＮＡ　ａｎｄ　Ｉｎａｃｔｉｖａｔｅｄ　Ｍｕｒｉｎｅ　Ｃｙｔｏｍｅｇａｌ' Ｊｏｕｒｎａｌ　ｏｆ　Ｖｉｒｏｌｏｇｙ Ｖｏｌ．７９，　Ｎｏ．１, 2005, ｐ．１５９-１７５ *

Also Published As

Publication number Publication date
EP2001516A4 (en) 2010-04-28
US8501194B2 (en) 2013-08-06
WO2007106404A3 (en) 2008-03-20
US20100272752A1 (en) 2010-10-28
EP2001516A2 (en) 2008-12-17
WO2007106404A2 (en) 2007-09-20
CA2645507A1 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
JP2009529576A (ja) 持続感染または潜伏感染を引き起こすウイルスに対するワクチン
Manickan et al. DNA Vaccines− a Modern Gimmick or a Boon to Vaccinology?
CN103889462B (zh) 作为cmv疫苗的条件性复制型巨细胞病毒
US20090297555A1 (en) Recombinant human cytomegalovirus and vaccines comprising heterologous antigens
JP6109165B2 (ja) ヘルペスウイルスワクチンおよび使用方法
JP5845191B2 (ja) 単純ヘルペスウイルスワクチン
Krause et al. Herpesvirus vaccines: development, controversies, and applications
Claassen et al. Identification of a CD4 T cell epitope in the pneumonia virus of mice glycoprotein and characterization of its role in protective immunity
Ferenczy Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus
US20240156954A1 (en) Vaccine compositions and methods for treating hsv
US12290558B2 (en) SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens
US20150147355A1 (en) Compositions and Methods of Vaccination
Dempster et al. Preclinical safety evaluation of viral vaccines
BAMDAD et al. The Effect of Glycoprotein B DNA Immuniation on HSV-l Lethal Infection of BALB/c Mice
HK1078777B (en) Modified vaccinia virus ankara for the vaccination of neonates
HK1078777A1 (zh) 用於接种新生儿的改良的安卡拉痘苗病毒
HK1175807B (en) Herpes simplex virus vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090903

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130325